Plainsboro, NJ, United States of America

Matthew M Parris

USPTO Granted Patents = 1 


 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Matthew M Parris

Introduction

Matthew M Parris is a notable inventor based in Plainsboro, NJ (US). He has made significant strides in the field of medical technology, particularly in cancer treatment. His work focuses on innovative methods to combat pulmonary cancer, showcasing his dedication to improving patient outcomes.

Latest Patents

Matthew M Parris holds a patent for a groundbreaking invention titled "Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin." This invention provides methods for treating pulmonary cancer in a subject by administering a composition of inhalational lipid cisplatin (ILC) through inhalation. The lipid-complexed cisplatin aims to enhance the effectiveness of treatment and reduce the recurrence of cancer in patients.

Career Highlights

Matthew M Parris is associated with Eleison Pharmaceuticals, LLC, where he contributes his expertise in developing innovative cancer therapies. His work at the company reflects his commitment to advancing medical science and improving therapeutic options for patients suffering from pulmonary cancer.

Collaborations

Matthew collaborates with esteemed colleagues, including Forrest H Anthony and Edwin J Thomas. Their combined efforts in research and development further enhance the potential impact of their innovations in the medical field.

Conclusion

Matthew M Parris exemplifies the spirit of innovation in the medical technology sector. His contributions, particularly in the treatment of pulmonary cancer, highlight the importance of research and development in improving healthcare outcomes. His work continues to inspire advancements in cancer treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…